Symjepi (epinephrine) 0.3mg and 0.15mg Injections are now available in retail pharmacies, according to Sandoz. The Company initially launched Symjepi 0.3mg Injection in the institutional setting in January 2019 and has now extended availability to the retail level.
Symjepi is indicated for the emergency treatment of allergic reactions (Type 1), including anaphylaxis to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances and other allergens, as well as idiopathic or exercise-induced anaphylaxis.
Selection of the appropriate dosage strength of Symjepi is based on body weight. Patients weighing ≥30kg should use the 0.3mg strength, while those weighing 15 to 30kg should use the 0.15mg injection. Symjepi can be administered intramuscularly or subcutaneously into the anterolateral aspect of the thigh, and through clothing if necessary.
“Patients and healthcare professionals are trying to navigate this critical shortage of self-injectable epinephrine products, which is why Sandoz is immediately making Symjepi available in adult and pediatric doses to patients at their local pharmacies,” said Carol Lynch, President of Sandoz. “Our collaboration with retail partners will enable patients and their caregivers to conveniently access Symjepi, a cost-effective treatment option with a compact and user-friendly design.”
Symjepi is supplied as a single-dose prefilled syringe and device combination, an alternative to epinephrine auto-injectors. Prescribers will need to specify “epinephrine injection” rather than “epinephrine auto-injector” when writing prescriptions if they determine an epinephrine medicine alternative is appropriate for their patient.
For more information visit symjepi.com.
This article originally appeared on MPR